These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 940279)
1. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3. Massry SG; Stein R; Garty J; Arieff AI; Coburn JW; Norman AW; Friedler RM Kidney Int; 1976 Jun; 9(6):467-74. PubMed ID: 940279 [TBL] [Abstract][Full Text] [Related]
2. Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites: evidence for the requirement of 1,25(OH)2D3 and 24,25(OH)2D3. Massry SG; Tuma S; Dua S; Goldstein DA J Lab Clin Med; 1979 Jul; 94(1):152-7. PubMed ID: 469372 [TBL] [Abstract][Full Text] [Related]
3. Effect of parathyroid hormone and uremia on peripheral nerve calcium and motor nerve conduction velocity. Goldstein DA; Chui LA; Massry SG J Clin Invest; 1978 Jul; 62(1):88-93. PubMed ID: 659642 [TBL] [Abstract][Full Text] [Related]
4. Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Galceran T; Martin KJ; Morrissey JJ; Slatopolsky E Kidney Int; 1987 Dec; 32(6):801-7. PubMed ID: 3430963 [TBL] [Abstract][Full Text] [Related]
5. Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites. Somerville PJ; Kaye M Kidney Int; 1978 Sep; 14(3):245-54. PubMed ID: 723151 [TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
7. Regulation of intestinal vitamin D receptor expression in experimental uraemia: effects of parathyroidectomy and administration of PTH. Szabó A; Schmutz A; Pesian S; Schmidt-Gayk H; Ritz E; Reichel H Nephrol Dial Transplant; 1998 Feb; 13(2):340-9. PubMed ID: 9509444 [TBL] [Abstract][Full Text] [Related]
8. On the mechanisms for the selective action of vitamin D analogs. Dusso AS; Negrea L; Gunawardhana S; Lopez-Hilker S; Finch J; Mori T; Nishii Y; Slatopolsky E; Brown AJ Endocrinology; 1991 Apr; 128(4):1687-92. PubMed ID: 2004595 [TBL] [Abstract][Full Text] [Related]
9. Calcemic and phosphaturic response to parathyroid hormone in normal and chronically uremic dogs. Jacob AI; Gavellas G; Canterbury J; Bourgoignie JJ Kidney Int; 1982 Jul; 22(1):21-6. PubMed ID: 6896896 [TBL] [Abstract][Full Text] [Related]
10. [Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone]. Ritz E; Kreusser W; Boland R; Bommer J Klin Wochenschr; 1979 Oct; 57(19):1053-9. PubMed ID: 392179 [TBL] [Abstract][Full Text] [Related]
11. Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia. Olgaard K; Finco D; Schwartz J; Arbelaez M; Teitelbaum S; Avioli L; Klahr S; Slatopolsky E Kidney Int; 1984 Dec; 26(6):791-7. PubMed ID: 6335904 [TBL] [Abstract][Full Text] [Related]
12. Effects in vivo of vitamin D metabolites and 17 beta-estradiol on parathyroid hormone-dependent formation of adenosine 3',5'-monophosphate in rat bone. Marcus R; Orner FB; Brickman AS Endocrinology; 1980 Nov; 107(5):1593-9. PubMed ID: 6253269 [TBL] [Abstract][Full Text] [Related]
13. Abnormal expression and regulation of vitamin D receptor in experimental uremia. Szabó A; Ritz E; Schmidt-Gayk H; Reichel H Nephron; 1996; 73(4):619-28. PubMed ID: 8856261 [TBL] [Abstract][Full Text] [Related]
14. Abnormal skeletal response to parathyroid hormone in dogs with chronic uremia. Olgaard K; Arbelaez M; Schwartz J; Klahr S; Slatopolsky E Calcif Tissue Int; 1982 Jul; 34(4):403-7. PubMed ID: 6291732 [TBL] [Abstract][Full Text] [Related]
15. Hypercalcemia after nephrectomy in the dog: role of the kidneys and parathyroid glands. Tuma SN; Mallette LE J Lab Clin Med; 1983 Aug; 102(2):213-9. PubMed ID: 6864071 [TBL] [Abstract][Full Text] [Related]
16. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3. Finch JL; Brown AJ; Mori T; Nishii Y; Slatopolsky E J Bone Miner Res; 1992 Jul; 7(7):835-9. PubMed ID: 1642151 [TBL] [Abstract][Full Text] [Related]
17. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728 [TBL] [Abstract][Full Text] [Related]
18. Calcium metabolism of brain in acute renal failure. Effects of uremia, hemodialysis, and parathyroid hormone. Arieff AI; Massry SG J Clin Invest; 1974 Feb; 53(2):387-92. PubMed ID: 11344551 [TBL] [Abstract][Full Text] [Related]
19. Evidence that resistance to the calcemic action of parathyroid hormone in rats with acute uremia is caused by phosphate retention. Somerville PJ; Kaye M Kidney Int; 1979 Nov; 16(5):552-60. PubMed ID: 548599 [TBL] [Abstract][Full Text] [Related]
20. Serum calcium and bone: effect of PTH, phosphate, vitamin D and uremia. Levine BS; Rodríguez M; Felsenfeld AJ Nefrologia; 2014; 34(5):658-69. PubMed ID: 25259820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]